MA54150A - Compositions et méthodes de traitement de troubles dépendant des oestrogènes - Google Patents
Compositions et méthodes de traitement de troubles dépendant des oestrogènesInfo
- Publication number
- MA54150A MA54150A MA054150A MA54150A MA54150A MA 54150 A MA54150 A MA 54150A MA 054150 A MA054150 A MA 054150A MA 54150 A MA54150 A MA 54150A MA 54150 A MA54150 A MA 54150A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methods
- estrogen dependent
- dependent disorders
- treating estrogen
- Prior art date
Links
- 230000001419 dependent effect Effects 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756946P | 2018-11-07 | 2018-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54150A true MA54150A (fr) | 2021-09-15 |
Family
ID=68618113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054150A MA54150A (fr) | 2018-11-07 | 2019-11-06 | Compositions et méthodes de traitement de troubles dépendant des oestrogènes |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230067378A1 (fr) |
| EP (1) | EP3876943A2 (fr) |
| JP (1) | JP7459086B2 (fr) |
| KR (1) | KR20210100623A (fr) |
| MA (1) | MA54150A (fr) |
| SG (1) | SG11202104053TA (fr) |
| WO (1) | WO2020094698A2 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201992612A1 (ru) | 2017-06-05 | 2020-05-20 | Обсева С.А. | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза |
| DK3634419T3 (da) | 2017-06-05 | 2025-03-31 | Kissei Pharmaceutical | Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab |
| MA54058A (fr) | 2018-10-29 | 2021-09-08 | ObsEva SA | Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale |
| AU2020325655B2 (en) * | 2019-08-08 | 2025-09-11 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of estrogen-dependent disorders |
| BR112022023937A2 (pt) * | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
| CN119698409A (zh) * | 2022-08-16 | 2025-03-25 | 深圳市康哲生物科技有限公司 | 一种噻吩并嘧啶酮衍生物的盐型及晶型 |
| WO2026060502A1 (fr) * | 2024-09-23 | 2026-03-26 | Klautau Leite Ana Paula | Système de diagnostic par image de l'endométriose profonde et/ou de l'adénomyose, et procédé d'analyse d'examens d'image |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1300398E (pt) | 2000-07-05 | 2006-07-31 | Astellas Pharma Inc | Processos e composicoes para terapias do cancro, utilizando genes que codificam o interferao-beta |
| CN101153042A (zh) | 2003-01-29 | 2008-04-02 | 武田药品工业株式会社 | 噻吩并嘧啶化合物及其用途 |
| EP1646389B1 (fr) | 2003-07-07 | 2008-09-10 | Neurocrine Biosciences, Inc. | Derives de pyrimidine-2, 4-dione utilises comme antagonistes du recepteur d'hormone liberant de la gonadotrophine |
| RU2418803C2 (ru) | 2005-10-19 | 2011-05-20 | Киссеи Фармасьютикал Ко., Лтд. | Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине |
| EP2535342B1 (fr) | 2010-02-10 | 2014-08-06 | Kissei Pharmaceutical Co., Ltd. | Sel de dérivé hétérocyclique condensé et cristal de celui-ci |
| JP6268093B2 (ja) * | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| BR112019002513A2 (pt) | 2016-08-08 | 2019-05-14 | Kissei Pharmaceutical Co., Ltd. | uso e dosagem de agentes terapêuticos para endometriose |
| DK3634419T3 (da) * | 2017-06-05 | 2025-03-31 | Kissei Pharmaceutical | Doseringsregime omfattende en gonadotropin-frigørende hormon-antagonist til behandling af fibromer i uterus og reduktion af menstruationsblodtab |
| US11690854B2 (en) * | 2018-04-19 | 2023-07-04 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
-
2019
- 2019-11-06 JP JP2021523696A patent/JP7459086B2/ja active Active
- 2019-11-06 SG SG11202104053TA patent/SG11202104053TA/en unknown
- 2019-11-06 EP EP19805904.0A patent/EP3876943A2/fr active Pending
- 2019-11-06 US US17/291,192 patent/US20230067378A1/en active Pending
- 2019-11-06 KR KR1020217017190A patent/KR20210100623A/ko not_active Withdrawn
- 2019-11-06 WO PCT/EP2019/080362 patent/WO2020094698A2/fr not_active Ceased
- 2019-11-06 MA MA054150A patent/MA54150A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202104053TA (en) | 2021-05-28 |
| JP2022506368A (ja) | 2022-01-17 |
| JP7459086B2 (ja) | 2024-04-01 |
| EP3876943A2 (fr) | 2021-09-15 |
| WO2020094698A3 (fr) | 2020-08-06 |
| KR20210100623A (ko) | 2021-08-17 |
| WO2020094698A2 (fr) | 2020-05-14 |
| US20230067378A1 (en) | 2023-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| EP3902536A4 (fr) | Compositions et méthodes de traitement de troubles neurodégénératifs | |
| EP3328376A4 (fr) | Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique | |
| EP3500267A4 (fr) | Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs | |
| EP3389725A4 (fr) | Compositions et méthodes pour le traitement de maladies du système nerveux central | |
| EP3661553A4 (fr) | Méthodes et compositions pour le traitement des maladies à dépôts amyloïdes | |
| EP3423100A4 (fr) | Compositions destinées à traiter l'inflammation et méthodes de traitement associées | |
| EP3727403A4 (fr) | Méthodes intracanalaires de traitement de troubles du sein | |
| EP3368088C0 (fr) | Compositions et méthodes pour le traitement de troubles du peroxisome et de leucodystrophies | |
| MA51056A (fr) | Compositions et méthodes pour le traitement d'affections métaboliques | |
| EP3692023A4 (fr) | Composés benzothiazol et méthodes d'utilisation de ceux-ci pour traiter des troubles neurodégénératifs | |
| EP3518923A4 (fr) | Méthodes de traitement de troubles mitochondriaux et métaboliques | |
| EP3600285A4 (fr) | Compositions topiques et méthodes de traitement | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3801768A4 (fr) | Méthodes de traitement de troubles du hyperprolifératifs malins | |
| EP3313417A4 (fr) | Méthodes de traitement de troubles auto-immuns et allo-immuns | |
| EP3331499A4 (fr) | Composition et méthode de traitement de troubles métaboliques | |
| EP3826650A4 (fr) | Méthodes de traitement de troubles neurologiques | |
| EP3952851A4 (fr) | Composés et méthodes de traitement de troubles inflammatoires | |
| EP3979996A4 (fr) | Méthodes et compositions de traitement de troubles de la vue | |
| EP3334710A4 (fr) | Compositions et méthodes de traitement et de prévention de troubles neurodégénératifs | |
| EP3442554A4 (fr) | Compositions et méthodes pour le traitement de troubles associés à la néovascularisation | |
| EP3364965A4 (fr) | Méthodes et compositions pour le traitement de maladies neurodégénératives | |
| EP3518951A4 (fr) | Compositions et méthodes pour le traitement d'affections orthopédiques | |
| EP3917623A4 (fr) | Compositions et méthodes pour le traitement de troubles neurocognitifs |